Skip to main content
. 2023 Sep 7;28(10):875–884. doi: 10.1093/oncolo/oyad257

Table 4.

Adverse-effects of CAPTEM chemotherapy (n = 308).

Grade 1, 2
n (%)
Grade 3, n (%) Grade 4, n (%) Treatment interruption, n (%)
Decreased platelet count 34 (11.0) 8 (2.6) 3 (1.0) 3 (1.0)
Decreased neutrophil count 34 (11.0) 1 (0.3) 3 (1.0) 4 (1.3)
Decreased lymphocyte count 40 (12.9) 3 (1.0)
Anemia 85 (27.6) 10 (3.2)
Fatigue 127 (41.3) 10 (3.2) 1 (1.2) 3 (1.0)
Nausea/vomiting 116 (37.7) 14 (4.5) 5 (1.6)
Constipation 11 (3.5) 1 (0.3)
Gastrointestinal hemorrhage 4 (1.3) 2 (0.6) 2 (0.6)
Diarrhea 34 (11.0) 3 (1.0) 2 (0.6) 2 (0.6)
Anorexia 91 (29.6) 4 (1.3) 1 (0.3) 1 (1.2)
Abdominal pain 27 (8.8) 2 (0.6) 1 (0.3) 2 (0.6)
Fever 4 (6.8)
Oral mucositis 42 (13.6) 4 (1.3) 2 (0.6)
Pruritis 4 (6.8)
Skin rash 2 (3.4)
Palmar-plantar erythrodysesthesia 58 (18.8) 4 (1.3) 1 (1.2)
Increased blood bilirubin 15 (4.8) 5 (1.6) 1 (0.3) 1 (1.2)
Increased alkaline phosphatase 22 (7.1) 4 (1.3)
Increased AST 41 (13.3) 2 (0.6) 1 (1.2)
Increased ALT 32 (10.4) 1 (0.3) 1 (1.2)
Dehydration 2 (2.4) 2 (2.4)